Propanc Biopharma, INC 8-K filings

Propanc Biopharma, Inc. announced the retirement of Annie Van Broekhoven from its Board of Directors and the appointment of Carlo Campiciano, a seasoned accountant with extensive experience in capital raising and financial strategy.

Propanc Biopharma, Inc. announced the appointment of Dr. Ralf Brandt, a seasoned pharmaceutical and oncology research executive, to its Board of Directors following Dr. Julian Kenyon's retirement.

Propanc Biopharma, Inc. received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Propanc Biopharma, Inc. completed a private placement with Hexstone Capital LLC, raising $1,000,099 through the sale of Series C Preferred Stock and a Warrant.

Propanc Biopharma, Inc. entered into a Securities Purchase Agreement with Hexstone Capital LLC for a private placement of Series C Preferred Stock and Warrants to fund general corporate purposes.

Propanc Biopharma, Inc. successfully closed its $4 million public offering and uplisted its common stock to the Nasdaq Capital Market under the symbol PPCB.

Propanc Biopharma, Inc. announced the appointment of Ms. Jeannine Zimmerman as its new Chief Financial Officer, effective August 13, 2025.

Propanc Biopharma, Inc. has entered into a convertible promissory note agreement for $112,350 at a 10% interest rate with punitive default and conversion terms, signaling potential financial distress and significant future dilution.

Propanc Biopharma Inc. has issued an $82,500 promissory note with a 10% annual interest rate and a significant original issue discount to Ionic Ventures, LLC, for general working capital, due September 15, 2025.

Propanc Biopharma, Inc. has entered into a Securities Purchase Agreement to issue a convertible promissory note for $58,000, incurring a principal amount of $67,860 and a one-time 15% interest charge, with a maturity date of April 16, 2026.

Propanc Biopharma, Inc. has entered into a $25,000 convertible redeemable note with GEEBIS CONSULTING, LLC and a short-term AU$13,188 loan with a Board Member to fund general working capital.

Propanc Biopharma Inc. has entered into a material definitive agreement for a $60,000 principal promissory note, purchased for $50,000, to fund general working capital, signaling a high cost of capital.

Propanc Biopharma, Inc. entered into a promissory note agreement for $90,000 and extended the maturity date of a previous note to June 15, 2025.

Propanc Biopharma, Inc. has entered into a securities purchase agreement for a $55,000 convertible note and other financing arrangements to bolster its working capital.

Propanc Biopharma, Inc. has entered into a securities purchase agreement to issue a convertible promissory note for $33,000 to GS Capital Partners, LLC, aimed at enhancing the company's working capital.

Propanc Biopharma, Inc. has entered into securities purchase agreements with investors to raise $108,000 through the issuance of convertible promissory notes, aimed at enhancing the company's working capital.

Propanc Biopharma has entered into two securities purchase agreements to secure a total of $61,000 in convertible debt financing for working capital.

Propanc Biopharma has entered into a loan agreement for $175,000 AUD to address existing debt, regulatory expenses, and general working capital needs.

Propanc Biopharma has entered into a securities purchase agreement for a $33,000 convertible note to fund general working capital.

Propanc Biopharma, Inc. has entered into a loan agreement with a board member for $85,000 AUD to be used for general working capital.

Propanc Biopharma has entered into a securities purchase agreement for a $33,000 convertible note to fund general working capital.

Propanc Biopharma has secured a $150,000 AUD loan with a 12% interest rate to bolster its working capital.

Propanc Biopharma has entered into a securities purchase agreement, securing $30,375 in funding through a convertible promissory note with a principal amount of $33,750.

Propanc Biopharma has entered into a securities purchase agreement, securing $41,000 in funding through the issuance of a convertible promissory note with a principal amount of $49,200.

Propanc Biopharma has obtained two short-term loans totaling $120,000 AUD to bolster its working capital.

Propanc Biopharma has obtained two loans totaling $120,000 AUD to bolster its working capital.

Propanc Biopharma has entered into a securities purchase agreement, securing $41,000 in funding through the issuance of a convertible promissory note with a principal amount of $49,200.

Propanc Biopharma has extended the maturity date of a $177,980 promissory note with Ionic Ventures to September 30, 2024, retroactively addressing a previous default.

Propanc Biopharma has entered into a securities purchase agreement, securing a $27,500 convertible note to bolster its working capital.

Propanc Biopharma, Inc. has updated its corporate overview and company presentation, making the updated materials available to the public.